Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) EBITDA (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of EBITDA data on record, last reported at -$54.2 million in Q1 2026.

  • On a quarterly basis, EBITDA fell 79.9% to -$54.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$186.0 million, a 44.81% decrease, with the full-year FY2025 number at -$162.0 million, down 24.9% from a year prior.
  • EBITDA reached -$54.2 million in Q1 2026 per OLMA's latest filing, down from -$46.0 million in the prior quarter.
  • Over the last five years, EBITDA for OLMA hit a ceiling of -$19.6 million in Q2 2023 and a floor of -$54.2 million in Q1 2026.
  • A 5-year average of -$32.2 million and a median of -$30.5 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 104.97% in 2022, then surged 41.61% in 2023.
  • Tracing OLMA's EBITDA over 5 years: stood at -$25.3 million in 2022, then dropped by 3.42% to -$26.2 million in 2023, then decreased by 29.42% to -$33.9 million in 2024, then crashed by 35.64% to -$46.0 million in 2025, then decreased by 17.85% to -$54.2 million in 2026.
  • Business Quant data shows EBITDA for OLMA at -$54.2 million in Q1 2026, -$46.0 million in Q4 2025, and -$42.0 million in Q3 2025.